Abstract
Cardiopulmonary arrest is one of the leading causes of death and disability, primarily occurring in the aged population. Numerous global cerebral ischemia animal models induce neuronal damage similar to cardiac arrest. These global cerebral ischemia models range from vessel occlusion to total cessation of cardiac function, both of which have allowed for the investigation of this multifaceted disease and detection of numerous agents that are neuroprotective. Synapses endure a variety of alterations after global cerebral ischemia from the resulting excitotoxicity and have been a major target for neuroprotection; however, neuroprotective agents have proven unsuccessful in clinical trials, as neurological outcomes have not displayed significant improvements in patients. A majority of these neuroprotective agents have specific neuronal targets, where the success of future neuroprotective agents may depend on non-specific targets and numerous cognitive improvements. This review focuses on the different models of global cerebral ischemia, neuronal synaptic alterations, synaptic neuroprotection and behavioral tests that can be used to determine deficits in cognitive function after global cerebral ischemia.
Keywords: Aging, cardiac arrest, global cerebral ischemia, hippocampus, neuroprotection, synapse
Current Drug Targets
Title:Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Volume: 14 Issue: 1
Author(s): Jake T. Neumann, Charles H. Cohan, Kunjan R. Dave, Clinton B. Wright and Miguel A. Perez-Pinzon
Affiliation:
Keywords: Aging, cardiac arrest, global cerebral ischemia, hippocampus, neuroprotection, synapse
Abstract: Cardiopulmonary arrest is one of the leading causes of death and disability, primarily occurring in the aged population. Numerous global cerebral ischemia animal models induce neuronal damage similar to cardiac arrest. These global cerebral ischemia models range from vessel occlusion to total cessation of cardiac function, both of which have allowed for the investigation of this multifaceted disease and detection of numerous agents that are neuroprotective. Synapses endure a variety of alterations after global cerebral ischemia from the resulting excitotoxicity and have been a major target for neuroprotection; however, neuroprotective agents have proven unsuccessful in clinical trials, as neurological outcomes have not displayed significant improvements in patients. A majority of these neuroprotective agents have specific neuronal targets, where the success of future neuroprotective agents may depend on non-specific targets and numerous cognitive improvements. This review focuses on the different models of global cerebral ischemia, neuronal synaptic alterations, synaptic neuroprotection and behavioral tests that can be used to determine deficits in cognitive function after global cerebral ischemia.
Export Options
About this article
Cite this article as:
T. Neumann Jake, H. Cohan Charles, R. Dave Kunjan, B. Wright Clinton and A. Perez-Pinzon Miguel, Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction, Current Drug Targets 2013; 14 (1) . https://dx.doi.org/10.2174/1389450111314010004
DOI https://dx.doi.org/10.2174/1389450111314010004 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice
Current Cardiology Reviews Promises of Lipid-based Drug Delivery Systems in the Management of Breast Cancer
Current Pharmaceutical Design Calcium Homeostasis and Kinetics in Heart Failure
Medicinal Chemistry Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2
Current Pharmacogenomics Editorial: Targeting Neuregulin1 and HER Receptor Tyrosine Kinases for Therapy of Breast Cancer and Heart Failure
Current Pharmaceutical Design Regulatory Light Chains of Striated Muscle Myosin. Structure, Function and Malfunction
Current Drug Targets - Cardiovascular & Hematological Disorders New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Alterations and Neuropsychiatric Disorders
Current Medicinal Chemistry Effects of a Long-Term Treatment with an Antioxidant Pyridoindole on Vascular Responsiveness in Diabetes-Induced Aging Rats
Current Aging Science Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Takotsubo Cardiomyopathy
Current Pharmaceutical Design Editorial (Thematic Issue: Recent Advances in Management of Myocarditis)
Current Pharmaceutical Design Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design Emerging Roles of Meis1 in Cardiac Regeneration, Stem Cells and Cancer
Current Drug Targets